GENE EDITING 101
All Companies
🇨🇳

CorrectSequence Therapeutics

Private

Transformer base editing from China

CorrectSequence has developed a proprietary transformer Base Editor (tBE) platform for next-generation gene editing therapies. Their lead candidate CS-101 for beta-hemoglobinopathies received IND approval from China's NMPA, making them one of the first Chinese companies to advance base editing into clinical trials.

Founded2019
HQShanghai, China
CEOLiu Mingzhao
StatusPrivate
Total Funding$80M

Pipeline

Drug / ProgramIndicationPhaseTechnology
CS-101Beta-HemoglobinopathiesPhase 1Transformer Base Editing

Key People

Liu MingzhaoCEO & Co-founder

Related Articles

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?
Biotech Companies
Market Analysis

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?

A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.

Mar 16, 20266 min read